NCT07941531
T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Nov 18, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.
All 1 version: 1 with changes below. See every version on ClinicalTrials.gov ↗
- Study First Submitted
Endpoints
Primary
Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm A)
Timeframe: up to 4 weeks after CD7CAR T-cell infusion
Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm B)
Timeframe: up to 4 weeks after CD7CAR T-cell infusion
Arms and interventions
Arm AExperimental
patients will receive autologous CD7-CAR T-cells
Arm BExperimental
Patients will receive lymphodepleting chemotherapy (Cy/Flu), followed by an infusion of CD7-CAR T cells.
Drugs: Fludarabine, Cyclophosphamide, Mesna
Devices: CliniMACS
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States